Brendan

Brendan from TD Securities also asked about customer reception of Ginkgo's Datapoints offering and anticipated tailwinds for this business segment over the next year.

Answer

Co-Founder and CEO Jason Kelly stated that the Datapoints offering has been well-received, finding a sweet spot in providing large datasets for bioAI models. He highlighted the impact of reasoning models on lab automation and the need for proprietary data to build strong bioAI models, noting that Ginkgo is a leader in providing these datasets to pharma and biotech ML teams.

Brendan at TD Securities inquired about customer reception of Ginkgo's Datapoints offering and anticipated material tailwinds for this business segment over the next 12 months.

Answer

Jason Kelly, Co-Founder and CEO, stated that the Datapoints offering has been very well-received, especially for generating large datasets crucial for training bioAI models. He highlighted strong interest from large pharma and biotech ML teams, positioning Ginkgo as a leader in providing these essential datasets.

Brendan asked for the latest FDA visibility regarding the mid-year launches of the CT/NG and Colli-Pee products, and any insights into the potential revenue ramp in the second half of the year. He also inquired about the traction and opportunities for expanding beyond public health settings into clinical environments like urgent cares and hospitals, specifically for the Hep C test.

Answer

Carrie Eglinton Manner (President and CEO) reiterated the target for a mid-year launch and a revenue ramp in the second half, acknowledging the inherent uncertainty in the regulatory review process and declining to provide specific timing beyond quarterly guidance. She expressed encouragement regarding the progress in expanding customer segments beyond public health into clinical settings (emergency rooms, urgent care) for the syndemic approach involving HIV, HCV, and syphilis.

Brendan from Citi asked for the latest FDA visibility regarding the mid-year product launches for CT/NG and Colli-Pee, and any insights into the potential revenue ramp in the second half of 2026. He also inquired about the traction and evolution of OraSure's expansion beyond public health settings into clinical areas like urgent care and hospitals for tests such as Hep C.

Answer

President and CEO Carrie Eglinton Manner stated that the company is still working towards a mid-year launch and second-half revenue ramp, but cautioned against providing specific timing due to regulatory review uncertainties. She also expressed encouragement regarding progress in expanding customer segments beyond public health into clinical settings, noting increased focus on HIV, HCV, and syphilis testing in emergency rooms and urgent care.

Brendan from Cantor Fitzgerald sought details on the potential registrational pathway for REC-4881, including FDA alignment, regulatory updates, and patient population considerations.

Answer

Najat Khan, CEO and President, confirmed the company is on track for initial FDA engagement in H1 2026 to discuss registrational study design, patient population, and endpoints, leveraging compelling durability and polyp burden reduction data, along with natural history data. She also noted the 18-and-over cohort is recruiting, and dose optimization efforts are underway, with more data expected in H1 2027.

Brendan inquired about the amount of capital expected to be freed up upon the full transfer of the Rithm portfolio.

Answer

Glen Messina, Chair, President, and CEO, clarified that subservicing itself does not free up capital as there is no investment in the portfolio. He noted that the sale of the reverse mortgage MSRs to Finance of America Reverse is expected to free up approximately $100 million in capital.